Clinical Trials in Cancer

In 2007 the market for anti-cancer drugs was worth around $35 billion, and is predicted to rise much further in coming years.

Developing and commercialising oncology drugs to take a part of this market requires extensive clinical research to prove safety and efficacy. SMi’s 7th Annual Clinical Trials in Cancer Conference provides a great opportunity to hear from leaders in this field. This year’s event will have two main focuses:

Adaptive Designs in Oncology –

60% of respondents to a recent survey said they either were planning on implementing or had already implemented adaptive methods into their clinical trials. With a number of presentations and case studies on this exciting topic, the conference will be a great place to learn the latest thinking on the specific application of Bayesian methods to oncology drug development.

Biomarkers, imaging and diagnostics –

Using biomarkers to measure pharmacokinetics and drug response is an increasingly necessary part of many clinical trials. Surrogate endpoints enable efficacy to be proved more easily and cheaply, and imaging technologies are becoming an increasingly useful quantitative tool. Diagnostics technologies are also allowing the possibility of personalised medicine for cancer treatment. Presentations on these topics will set out the latest technical advances and applications to clinical research.

New Speaker Confirmed!

• Vinka Ljubimir, Oncology MDC Clinical Operations, GlaxoSmithKline

Confirmed Speakers Include:

• Mark Rolfe, Vice President, Discovery Oncology, Millennium Pharmaceuticals
• Brian Schwartz, Senior Vice President and Chief Medical Officer, Ziopharm Oncology
• Leon Terstappen, Senior Vice President of Research and Development, and Chief Scientific Officer, Immunicon Corporation
• Karl-Herman Schlingensiepen, CEO, Antisense Pharma
• Garrett Hampton, Executive Director, Molecular and Medical Sciences, Celgene Corporation
• William Gallagher, Associate Professor, Cancer Biology, University College Dublin, and CEO OncoMark Ltd.
• Karol Sikora, Medical Director, CancerPartners UK, and Professor of Cancer Medicine, Imperial College
• Shethah Morgan, Research Clinical Scientist, Clinical Development - Discovery Medicine, AstraZeneca
• Andy Grieve, Professor, Kings College London
• Nikki Fernandez, Global Product Statistician, AstraZeneca
• Michala Worrell, Clinical Project Manager, AstraZeneca
• David Huckle, Chief Executive, Adams Business Associates
• Geoff Boxer, Laboratory Manager & LTN Business Fellow (Oncology), Cancer Research UK Targeting and Imaging Group, UCL Cancer Institute
• Dana Ghiorghiu, Associate Research Physician, Imaging, AstraZeneca

This Conference is aimed at Directors, heads and managers of:

• Clinical Research
• Discovery Medicine
• Cancer & Infection
• Pharmacology
• Clinical Technology
• Clinical Diagnostics
• Oncology
• Diagnostic/Oncology/Molecular/Biomedical Imaging
• Specialized Therapeutics
• Oncology technology
• Clinical strategy
• Biostatistics
• Translational Medicine

If you’re interested in speaking opportunities at this event, please contact Robin Walsh on +44 (0) 20 7827 6086 or rwalsh@smi-online.co.uk. If you’re interested in exhibiting at this event, please contact Alia Malick on +44 (0) 20 7827 6168 or amalick@smi-online.co.uk